查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574770

诊断市场：按产品类型、应用和最终用户划分 - 2025-2030 年全球预测

Diagnostic Substances Market by Product Type (Instruments, Kits & Assays, Reagents), Application (Clinical Diagnostics, Forensic, Research), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年诊断市值为2048.4亿美元，预计到2024年将达到2156.3亿美元，复合年增长率为6.02%，到2030年将达到3085.3亿美元。

诊断市场包括用于疾病诊断的材料，例如试剂、校准品、控製材料、套件和相关设备。随着慢性病和感染疾病的增加，诊断试剂用于临床实验室、医院、即时检测和研究机构，以进行彻底的评估、健康监测和有效的患者管理。最终用途产业涵盖医疗保健、生物技术和製药，推动了从常规测试到高阶分子诊断的应用。关键的成长要素包括健康意识提高导致的需求增加、促进床边生物感测器等创新产品的技术进步以及加速市场进入的有利法规环境。此外，疾病发生率的增加需要准确、快速的诊断，以改善医疗保健结果并降低成本。

主要市场统计
基准年[2023] 2048.4亿美元
预测年份 [2024] 2156.3亿美元
预测年份 [2030] 3085.3亿美元
复合年增长率（%） 6.02%

在基因组学和蛋白​​质组学进步的推动下，个人化医疗的引入带来了新的商机，从而推动了对专业诊断的需求。人工智慧和巨量资料分析在诊断中的使用为精准医疗和即时健康监测提供了巨大的市场潜力。然而，高昂的开发成本、严格的监管环境和资料隐私问题等挑战可能会阻碍市场的进步。将新技术整合到现有系统中的复杂性进一步增加了营运障碍。鼓励创新和研究开发具有更高灵敏度和特异性的照护现场诊断设备，针对资源有限的环境，解决发展中地区未满足的需求。与实验室晶片技术一起，生物标誌物的发现和检验提供了一条充满希望​​的增长途径。

儘管存在这些障碍，但鑑于医疗保健成本不断上升以及医疗保健提供者和技术公司之间为简化诊断程序而进行的合作，诊断市场仍有望扩大。为了成功驾驭不断变化的市场格局，建议采用强调扩充性、永续性和以患者为中心的解决方案的适应性方法。此外，采用环保生产流程和数位健康创新可以确保产业参与者的可持续竞争优势。

市场动态：揭示快速发展的诊断市场的关键市场洞察

供需的动态交互作用正在改变诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 诊断技术的进步和慢性病盛行率的上升推动市场成长
    • 增加政府措施和资金以改善全球医疗保健基础设施
    • 扩大照护现场诊断设备的采用，以改善患者照护和治疗结果
    • 对疾病早期检测和个人化医疗的需求不断增长推动市场扩张
  • 市场限制因素
    • 不断变化的医疗保健政策和报销问题对诊断市场的成长产生负面影响
    • 欠发达地区先进诊断技术的取得和可用性有限阻碍了市场潜力
  • 市场机会
    • 癌症治疗中个人化医疗的先进诊断生物标记
    • 用于在偏远地区快速检测感染疾病的照护现场诊断测试
    • 使用人工智慧进行预测诊断以早期发现神经退化性疾病
  • 市场挑战
    • 缺乏熟悉诊断的熟练专业人员会影响市场成长和创新

波特五力：驾驭诊断市场的策略工具

波特的五力框架是了解诊断市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解诊断市场的外部影响

外部宏观环境因素在塑造诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解诊断药物市场的竞争状况

诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵诊断市场供应商绩效评估

FPNV定位矩阵是评估诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 规划诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 诊断技术的进步和慢性病的增加推动市场成长
      • 政府加强并提供资金以改善世界各地的医疗基础设施
      • 更多地采用照护现场诊断设备以改善患者护理和治疗结果
      • 对疾病早期检测和个人化医疗的需求不断增长正在推动市场扩张
    • 抑制因素
      • 不断变化的医疗保健政策和报销问题将对诊断市场的成长产生负面影响
      • 发展中地区先进诊断技术的取得和可用性有限，限制了市场潜力。
    • 机会
      • 癌症治疗中个人化医疗的先进诊断生物标记
      • 用于快速检测偏远地区感染疾病的照护现场诊断测试
      • 人工智慧驱动的预测诊断用于神经退化性疾病的早期检测
    • 任务
      • 缺乏具有诊断专业知识的熟练专业人员会影响市场成长和创新。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章诊断市场：依产品类型

  • 装置
    • 分析仪
    • 次世代定序
    • PCR机
  • 套件和检测
    • 酵素连结免疫吸附测定试剂套件
    • 横向流动化验
    • PCR试剂套件
  • 试剂
    • 抗体
    • 胜肽
    • 蛋白质

第七章诊断市场：依应用分类

  • 临床诊断
    • 心臟病学
    • 感染疾病
    • 肿瘤学
  • 法医学
    • 病理
    • 毒理学
  • 研究
    • 药物发现
    • 基因组学
    • 蛋白质体学

第 8 章诊断市场：依最终使用者划分

  • 诊断实验室
    • 医院实验室
    • 独立实验室
  • 医院/诊所
    • 私立医院
    • 公立医院
  • 製药公司
    • 临床试验
    • 药物开发
  • 调查机构
    • 学术研究
    • 政府调查

第九章 北美、南美诊断试剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Cepheid
  • 7. Danaher Corporation
  • 8. DiaSorin SpA
  • 9. Genomic Health Inc.
  • 10. Hoffmann-La Roche AG
  • 11. Hologic Inc.
  • 12. Illumina Inc.
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. PerkinElmer Inc.
  • 16. Qiagen NV
  • 17. Quidel Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation
  • 20. Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C040C

The Diagnostic Substances Market was valued at USD 204.84 billion in 2023, expected to reach USD 215.63 billion in 2024, and is projected to grow at a CAGR of 6.02%, to USD 308.53 billion by 2030.

The diagnostic substances market encompasses materials used for diagnosing diseases, encompassing reagents, calibrators, control materials, kits, and related instruments. Necessitated by the increasing prevalence of chronic and infectious diseases, diagnostic substances are applied in clinical laboratories, hospitals, point-of-care testing, and research institutions for conducting meticulous assessments, monitoring health conditions, and ensuring effective patient management. End-use industries span healthcare, biotechnology, and pharmaceuticals, driving diverse applications from routine tests to advanced molecular diagnostics. Key growth influencers include escalating demand due to rising health awareness, technological advancements fostering innovative products like point-of-care biosensors, and supportive regulatory environments accelerating market entry. Additionally, the growing incidence of diseases necessitates accurate, swift diagnosis to improve healthcare outcomes and reduce costs.

KEY MARKET STATISTICS
Base Year [2023] USD 204.84 billion
Estimated Year [2024] USD 215.63 billion
Forecast Year [2030] USD 308.53 billion
CAGR (%) 6.02%

Emerging opportunities are notably visible in the adoption of personalized medicine, fueled by genomic and proteomic advancements, propelling demand for specialized diagnostic substances. Leveraging artificial intelligence and big data analytics in diagnostics offers substantial market potential for precision medicine and real-time health monitoring. However, challenges such as high development costs, stringent regulatory landscapes, and data privacy issues can impede market progression. Complexities in integrating new technologies within existing systems further pose operational hurdles. Encouragement of innovation and research is directed towards developing point-of-care diagnostic devices with enhanced sensitivity and specificity, targeting resource-constrained settings to cater to unmet needs in developing regions. Exploring biomarker discovery and validation, alongside lab-on-a-chip technologies, presents promising avenues for growth.

Despite these hurdles, the diagnostic substances market is poised for expansion, given the increasing healthcare expenditures, alongside collaborations between healthcare providers and technological firms striving to streamline diagnostic procedures. An adaptable approach emphasizing scalability, sustainability, and patient-centric solutions is recommended to navigate the evolving market landscape successfully. Subsequently, embracing eco-friendly production processes and digital health innovations ensures sustained competitive advantage for industry participants.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diagnostic Substances Market

The Diagnostic Substances Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in diagnostic technologies and rising prevalence of chronic diseases boosting market growth
    • Increasing government initiatives and funding to improve healthcare infrastructure worldwide
    • Growing adoption of point-of-care diagnostic devices to enhance patient care and outcomes
    • Rising demand for early disease detection and personalized medicine driving market expansion
  • Market Restraints
    • Evolving healthcare policies and reimbursement issues negatively impact diagnostic substances market growth
    • Limited accessibility and availability of advanced diagnostic technologies in underdeveloped regions hinder market potential
  • Market Opportunities
    • Advanced diagnostic biomarkers for personalized medicine in cancer treatment
    • Point-of-care diagnostic tests for rapid infectious disease detection in remote areas
    • AI-driven predictive diagnostics for early detection of neurodegenerative diseases
  • Market Challenges
    • Limited availability of skilled professionals with expertise in diagnostic substances impacts market growth and innovation

Porter's Five Forces: A Strategic Tool for Navigating the Diagnostic Substances Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diagnostic Substances Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diagnostic Substances Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diagnostic Substances Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diagnostic Substances Market

A detailed market share analysis in the Diagnostic Substances Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diagnostic Substances Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diagnostic Substances Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diagnostic Substances Market

A strategic analysis of the Diagnostic Substances Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diagnostic Substances Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, Cepheid, Danaher Corporation, DiaSorin S.p.A., Genomic Health Inc., Hoffmann-La Roche AG, Hologic Inc., Illumina Inc., Merck KGaA, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen N.V., Quidel Corporation, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Diagnostic Substances Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments, Kits & Assays, and Reagents. The Instruments is further studied across Analyzers, Next-Generation Sequencing, and PCR Machines. The Kits & Assays is further studied across Elisa Kits, Lateral Flow Assays, and PCR Kits. The Reagents is further studied across Antibodies, Peptides, and Proteins.
  • Based on Application, market is studied across Clinical Diagnostics, Forensic, and Research. The Clinical Diagnostics is further studied across Cardiology, Infectious Diseases, and Oncology. The Forensic is further studied across Pathology and Toxicology. The Research is further studied across Drug Discovery, Genomics, and Proteomics.
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, Pharmaceutical Companies, and Research Institutes. The Diagnostic Laboratories is further studied across Hospital-Based Labs and Independent Labs. The Hospitals & Clinics is further studied across Private Hospitals and Public Hospitals. The Pharmaceutical Companies is further studied across Clinical Trials and Drug Development. The Research Institutes is further studied across Academic Research and Government Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in diagnostic technologies and rising prevalence of chronic diseases boosting market growth
      • 5.1.1.2. Increasing government initiatives and funding to improve healthcare infrastructure worldwide
      • 5.1.1.3. Growing adoption of point-of-care diagnostic devices to enhance patient care and outcomes
      • 5.1.1.4. Rising demand for early disease detection and personalized medicine driving market expansion
    • 5.1.2. Restraints
      • 5.1.2.1. Evolving healthcare policies and reimbursement issues negatively impact diagnostic substances market growth
      • 5.1.2.2. Limited accessibility and availability of advanced diagnostic technologies in underdeveloped regions hinder market potential
    • 5.1.3. Opportunities
      • 5.1.3.1. Advanced diagnostic biomarkers for personalized medicine in cancer treatment
      • 5.1.3.2. Point-of-care diagnostic tests for rapid infectious disease detection in remote areas
      • 5.1.3.3. AI-driven predictive diagnostics for early detection of neurodegenerative diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled professionals with expertise in diagnostic substances impacts market growth and innovation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diagnostic Substances Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
    • 6.2.1. Analyzers
    • 6.2.2. Next-Generation Sequencing
    • 6.2.3. PCR Machines
  • 6.3. Kits & Assays
    • 6.3.1. Elisa Kits
    • 6.3.2. Lateral Flow Assays
    • 6.3.3. PCR Kits
  • 6.4. Reagents
    • 6.4.1. Antibodies
    • 6.4.2. Peptides
    • 6.4.3. Proteins

7. Diagnostic Substances Market, by Application

  • 7.1. Introduction
  • 7.2. Clinical Diagnostics
    • 7.2.1. Cardiology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Oncology
  • 7.3. Forensic
    • 7.3.1. Pathology
    • 7.3.2. Toxicology
  • 7.4. Research
    • 7.4.1. Drug Discovery
    • 7.4.2. Genomics
    • 7.4.3. Proteomics

8. Diagnostic Substances Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
    • 8.2.1. Hospital-Based Labs
    • 8.2.2. Independent Labs
  • 8.3. Hospitals & Clinics
    • 8.3.1. Private Hospitals
    • 8.3.2. Public Hospitals
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Clinical Trials
    • 8.4.2. Drug Development
  • 8.5. Research Institutes
    • 8.5.1. Academic Research
    • 8.5.2. Government Research

9. Americas Diagnostic Substances Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diagnostic Substances Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Substances Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Cepheid
  • 7. Danaher Corporation
  • 8. DiaSorin S.p.A.
  • 9. Genomic Health Inc.
  • 10. Hoffmann-La Roche AG
  • 11. Hologic Inc.
  • 12. Illumina Inc.
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. PerkinElmer Inc.
  • 16. Qiagen N.V.
  • 17. Quidel Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. DIAGNOSTIC SUBSTANCES MARKET RESEARCH PROCESS
  • FIGURE 2. DIAGNOSTIC SUBSTANCES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIAGNOSTIC SUBSTANCES MARKET DYNAMICS
  • TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GOVERNMENT RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 266. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 279. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 292. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 303. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 304. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 319. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 329. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 330. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 331. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 332.